Gwendolyn Binder

Dr. Gwendolyn Binder joined the Instil Board in 2020. Dr. Binder is an R&D executive with specialized expertise in the discovery and early clinical development and optimization of engineered T cell therapies. Currently, Dr. Binder is the E.V.P. of Science and Technology at Cabaletta Bio, which is developing engineered T cells for B cell mediated autoimmune diseases. From 2011-2018, Dr. Binder established the U.S. arm of and served as Chief Technology Officer (CTO) for Adaptimmune, developing TCR-engineered T-cells for oncology. From 2006-2011, Dr. Binder served as the Director of Translational Research Operations for Carl June at the University of Pennsylvania, where she progressed multiple IND submissions for novel engineered T-cell therapies in HIV and oncology, including the CD19 CAR IND acquired by Novartis (now Kymriah), the first human gene editing IND, and three TCR engineered T cell therapy studies in oncology and HIV. From 2002-2005, Dr. Binder served as the Director of Scientific Affairs at VIRxSYS Corporation in Gaithersburg, Maryland, where she supported the development of the first clinical lentiviral vector used in humans, for the application of engineered T cell therapy for HIV. Dr. Binder studied viral immunology and translational research at the Johns Hopkins University in Baltimore, USA where she earned in Ph.D. in Cellular and Molecular Medicine in 2002.